Plural Amino Nitrogens Patents (Class 514/673)
  • Publication number: 20140294799
    Abstract: The composition includes, per gram of composition, less than 600, in particular less than 400 picomoles of biologically active polyamines, for use in the prevention or treatment of radiotherapy-induced pathologies of the skin or mucous membranes in a patient, in particular a human or an animal.
    Type: Application
    Filed: August 30, 2012
    Publication date: October 2, 2014
    Applicant: NUTRIALYS MEDICAL NUTRITION SA
    Inventors: Bernard Cipolla, Xavier Artignan
  • Patent number: 8834943
    Abstract: The present invention features compositions comprising at least one compound of the formula I or formula II: wherein R1, R2, R3, R4, and R5 independently, are selected from the group consisting of hydrogen, C1-C6 alkyl, C1-C6 hydroxyalkyl, or a cosmetically acceptable salt thereof, and the use thereof.
    Type: Grant
    Filed: November 30, 2010
    Date of Patent: September 16, 2014
    Assignee: Johnson & Johnson Consumer Companies, Inc.
    Inventors: Michael Southall, Katharine Martin, Phyllis Mitchell, Menas Kizoulis, Neena Tierney, Elvin R. Lukenbach, Binoy K. Bordoloi
  • Patent number: 8772341
    Abstract: Germicidal compositions containing one or more N,N-bis(3-aminopropyl) C6-C18 alkyl amines, such as N,N-bis(3-aminopropyl)dodecylamine, and methods of using the compositions for treatment or prevention of infectious hoof diseases are disclosed. The germicidal compositions remain active in the presence of manure, which eliminates the need to pre-clean the hooves before use, and have particular utility for treating or preventing papillomatous digital dermatitis, interdigital phlegmon, interdigital dermatitis, laminitis, white line disease, heel erosion and other hoof diseases.
    Type: Grant
    Filed: September 10, 2007
    Date of Patent: July 8, 2014
    Assignee: DeLaval Holding AB
    Inventors: Chris Foret, Alex Skender, Thomas C. Hemling
  • Publication number: 20140140932
    Abstract: The present disclosure provides functionalized magnetic nanoparticles (MNPs) comprising a functional group that binds to ?-amyloid deposits and/or neurofibrillary tangles. The present disclosure provides compositions comprising the functionalized MNPs, and methods of using the functionalized MNPs in imaging ?-amyloid deposits and neurofibrillary tangles.
    Type: Application
    Filed: April 4, 2012
    Publication date: May 22, 2014
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventor: Masoud Akhtari
  • Patent number: 8729133
    Abstract: This invention relates to a process of treating/affecting cancers that are particularly susceptible to radiation therapy by administering to a host in need of such treatment an amino acid and radiation therapy.
    Type: Grant
    Filed: February 14, 2007
    Date of Patent: May 20, 2014
    Assignee: Cornell University
    Inventor: Leandro Carlos A Cerchietti
  • Patent number: 8728504
    Abstract: A process for solubilizing hydrophobic active ingredients in aqueous medium, which comprises using, as an assistant, at least one hyperbranched polymer (A) which is obtainable by reacting at least one hyperbranched polymeric compound having at least one primary or secondary amino group per molecule (a), selected from (a1) hyperbranched polyamides and (a2) hyperbranched polyureas, with (b) at least one mono-, di- or oligosaccharide.
    Type: Grant
    Filed: February 4, 2011
    Date of Patent: May 20, 2014
    Assignee: BASF SE
    Inventors: Bernd Bruchmann, Holger Türk, Daniel Schönfelder, Monika Haberecht, Dietmar Appelhans, Victor Boyko
  • Publication number: 20140107218
    Abstract: The invention provides novel methods for maintaining eye health and ameliorating ophthalmic maladies in animals by administering to the animals an ophthalmic malady ameliorating amount of one or more polyamines. Generally, the polyamines are administered to the animals in amounts of from about 1 to about 200 mg/kg/day to ameliorate maladies such as cataracts and cloudy eye.
    Type: Application
    Filed: October 14, 2013
    Publication date: April 17, 2014
    Applicant: NESTEC SA
    Inventors: Scott Sherrill, Wei Wang
  • Publication number: 20140056951
    Abstract: Methods of treating or reducing biofilms, treating a biofilm-related disorder, and preventing biofilm formation using polyamines is described.
    Type: Application
    Filed: November 4, 2013
    Publication date: February 27, 2014
    Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Richard LOSICK, Illana KOLODKIN-GAL, Jon CLARDY, Shugeng CAO, Matt CABEEN, Roberto KOLTER, Liraz CHAI, Thomas BÖTTCHER
  • Publication number: 20140056952
    Abstract: Methods of treating or reducing biofilms, treating a biofilm-related disorder, and preventing biofilm formation using polyamines is described.
    Type: Application
    Filed: November 4, 2013
    Publication date: February 27, 2014
    Applicant: President and Fellows of Harvard College
    Inventors: Richard LOSICK, Illana KOLODKIN-GAL, Jon CLARDY, Shugeng CAO, Matt CABEEN, Roberto KOLTER, Liraz CHAI, Thomas BÖTTCHER
  • Publication number: 20130338098
    Abstract: A method for producing local analgesia in a subject having a site of local discomfort comprises administration of an aliphatic polyamine and, preferably, urea. A composition of the invention comprises an aliphatic polyamine and preferably urea. The polyamine can be an alkylamine, such as, preferably, putrescine. The composition can also include lidocaine and/or a copper containing component.
    Type: Application
    Filed: March 13, 2013
    Publication date: December 19, 2013
    Applicant: Dermal Therapy (Barbados) Inc.
    Inventor: Dermal Therapy (Barbados) Inc.
  • Publication number: 20130190340
    Abstract: Certain aspects of the invention relate to compounds, compositions and methods that are useful for treating or preventing a disease in a subject by enhancing the degradation of a protein. In other aspects, said compounds can be useful research tools for investigating protein degradation. In other aspects, said compounds are useful research tools for investigating protein function. In certain embodiments, the degraded protein is implicated in a disease or disorder whose pathology is related at least in part to the excessive expression of the protein or the expression of a mutant form of the protein.
    Type: Application
    Filed: June 30, 2011
    Publication date: July 25, 2013
    Applicant: Brandeis University
    Inventors: Lizbeth K. Hedstrom, Marcus Long, Deviprasad R. Gollapalli
  • Patent number: 8426474
    Abstract: Novel wash and carrier solutions ideally suited for topical administration (e.g., as wash solutions and as carrier solutions). The solutions described herein are non-toxic, non-irritating, isotonic, possess non-specific broad-spectrum antimicrobial properties, and have an alkaline pH. Also disclosed are sterile preparations of the solutions and methods of using the same.
    Type: Grant
    Filed: March 15, 2011
    Date of Patent: April 23, 2013
    Assignee: Teva Animal Health, Inc.
    Inventors: Richard Farng, Steven Mrha
  • Patent number: 8383682
    Abstract: A composition comprises surface-modified nanoparticles of at least one amphoteric metal oxide or oxyhydroxide. The nanoparticles bear, on at least a portion of their surfaces, a surface modification comprising (i) at least one surface modifier selected from lactate, thiolactate, and mixtures thereof, and (ii) at least one surface modifier selected from halide, nitrate, acetate, carbonate, formate, propionate, sulfate, bromate, perchlorate, tribromoacetate, trichloroacetate, trifluoroacetate, carboxylate comprising from one to about four alkyleneoxy moieties, chlorate, and mixtures thereof.
    Type: Grant
    Filed: December 16, 2008
    Date of Patent: February 26, 2013
    Assignee: 3M Innovative Properties Company
    Inventor: Timothy D. Dunbar
  • Patent number: 8198334
    Abstract: Methods for modulating macrophage proliferation in an individual afflicted with or at risk for an ocular disease such as ARMD are provided. The methods employ a polyamine analog, or salt or protected derivative thereof. Macrophage proliferation has been implicated in a number of serious disorders, including ARMD. The invention also provides methods for aiding diagnosis and monitoring therapy of an ocular disease such as ARMD.
    Type: Grant
    Filed: February 22, 2005
    Date of Patent: June 12, 2012
    Assignee: Pathologica LLC
    Inventor: Michael McGrath
  • Publication number: 20120015901
    Abstract: The present invention relates to a method of treating a life threatening condition in a critically ill human patient with a non-infectuous disorder, wherein the critically ill patient is a patient receiving enteral or parenteral nutrition, the method comprising the step of administering to said patient an autophagy inducing agent.
    Type: Application
    Filed: July 13, 2011
    Publication date: January 19, 2012
    Applicants: Katholieke Universiteit Leuven, K.U.Leuven R&D, Joanneum Research Forschungsgesellschaft mbH, University of Graz
    Inventors: Joris Winderickx, Greet Van Den Berghe, Jan Gunst, IIse Vanhorebeek, Lies Langouche, Tobias Eisenberg, Frank Madeo, Christophe Magnes, Frank Sinner
  • Patent number: 8084505
    Abstract: The present invention provides: a carbon nanohorn composite including a carbon nanohorn, a substance encapsulated in the carbon nanohorn, and a polyamine adsorbed by chemical reaction firmly to a surface functional group present on the opening part on the surface of the carbon nanohorn, wherein the release amount and release rate of the encapsulated substance can be controlled using the difference in size, substituent or three-dimensional structure of the polyamine, which is used as a plug; a method of controlling the release of the encapsulated substance; and a process for producing the carbon nanohorn composite. The release amount and release rate of the substance encapsulated in the carbon nanohorn composite is controlled by selecting a polyamine molecule, which plugs the opening part formed in the carbon nanohorn by oxidation, by its size, substituent or three-dimensional structure.
    Type: Grant
    Filed: July 3, 2007
    Date of Patent: December 27, 2011
    Assignee: NEC Corporation
    Inventors: Ryota Yuge, Hideki Yorimitsu, Masako Yudasaka, Sumio Iijima
  • Publication number: 20110290693
    Abstract: Therapeutic compositions, devices and protocols for the treatment of keloids and other abnormal scars with improved appearance and a much lower recurrence rate. A therapeutic drug delivery device comprises an injectable mixture of a fibroblast inhibitor such as corticosteroid and a slow release carrier such as milled gel sponge dispersed in a fluid medium such as biological saline. The composition can be injected perilesionally in the dermis following excision of the keloid or other scar tissue, to circumscribe the wound. The infiltration of the mixture around the wound can provide a slow release of the fibroblast inhibitor for an extended period of time until normal wound closure can dominate and keloid or abnormal scar recurrence is inhibited.
    Type: Application
    Filed: May 30, 2011
    Publication date: December 1, 2011
    Inventor: Canaan Vernon Lavelle Harris
  • Publication number: 20110280921
    Abstract: The present invention relates to hydrogels endowed with antibacterial properties, to be used for injection in damaged bones or in the production of antibacterial coatings of prostheses for implant in the human or animal body, obtained by loading with antibacterial agents hydrogels formed by derivatives of hyaluronic acid; the invention also relates to a kit of parts for producing the antibacterial hydrogels.
    Type: Application
    Filed: January 29, 2010
    Publication date: November 17, 2011
    Applicants: NOVAGENIT S.R.L., MERO S.R.L
    Inventors: Gaetano Giammona, Giovanna Pitarresi, Fabio Palumbo, Carlo Luca Romano, Enzo Meani, Edgardo Cremascoli
  • Patent number: 7994213
    Abstract: Disclosed are a coating agent for drug releasing stents, a method for preparing the same and a drug releasing stent coated therewith. The coating agent for drug releasing stents comprises nanoparticles with a biologically active material entrapped therein, wherein the particles are formed of a polyethyleneimine (PEI)-deoxycholic acid (DOCA) polymer (PDo) in which 1˜8 moles of DOCA are grafted per mole of PEI.
    Type: Grant
    Filed: May 28, 2008
    Date of Patent: August 9, 2011
    Assignees: Taewoong Medical Co., Ltd., Kyong-Min Shin
    Inventors: Kyong-Min Shin, Dong-ki Lee, Don-haeng Lee, Kun Na, Eun-ae Jo
  • Publication number: 20110152213
    Abstract: It has been discovered that certain natural mRNAs serve as metabolite-sensitive genetic switches wherein the RNA directly binds a small organic molecule. This binding process changes the conformation of the mRNA, which causes a change in gene expression by a variety of different mechanisms. Modified versions of these natural “riboswitches” (created by using various nucleic acid engineering strategies) can be employed as designer genetic switches that are controlled by specific effector compounds. Such effector compounds that activate a riboswitch are referred to herein as trigger molecules. The natural switches are targets for antibiotics and other small molecule therapies.
    Type: Application
    Filed: February 23, 2011
    Publication date: June 23, 2011
    Inventors: Ronald R. Breaker, Ali Nahvi, Narasimhan Sudarsan, Margaret S. Ebert, Wade Winkler, Jeffrey E. Barrick, John K. Wickiser
  • Publication number: 20110098284
    Abstract: The present invention provides a method of treating or preventing pain, inflammation or fever comprising administering to a subject in need of such treatment or prevention a therapeutically effective amount of one or more selected NSAIDs, in racemic, enantiomeric excess, or enantiomeric form, in combination with ethylenediamine and/or piperazine.
    Type: Application
    Filed: April 28, 2006
    Publication date: April 28, 2011
    Inventor: Najib Babul
  • Publication number: 20110091586
    Abstract: The present invention features compositions comprising at least one compound of the formula I or formula II: wherein R1, R2, R3, R4, and R5 independently, are selected from the group consisting of hydrogen, C1-C6 alkyl, C1-C6 hydroxyalkyl, or a cosmetically acceptable salt thereof, and the use thereof.
    Type: Application
    Filed: November 30, 2010
    Publication date: April 21, 2011
    Inventors: Michael Southall, Katharine Martin, Phyllis Mitchell, Menas Kizoulis, Neena Tierney, Elvin R. Lukenbach, Binoy K. Bordoloi
  • Patent number: 7928147
    Abstract: Novel wash and carrier solutions ideally suited for topical administration (e.g., as wash solutions and as carrier solutions). The solutions described herein are non-toxic, non-irritating, isotonic, possess non-specific broad-spectrum antimicrobial properties, and have an alkaline pH. Also disclosed are sterile preparations of the solutions and methods of using the same.
    Type: Grant
    Filed: April 11, 2003
    Date of Patent: April 19, 2011
    Assignee: Teva Animal Health, Inc.
    Inventors: Richard Farng, Steven Mrha
  • Publication number: 20110082076
    Abstract: Microparticle compositions comprising metal ion-lipid complexes for drug delivery are described including methods of making the microparticle compositions and methods of treating certain conditions and disease states by administering the microparticle compositions. The metal ion-lipid complexes can be combined with various drugs or active agents for therapeutic administration. The microparticle compositions of the present invention have superior stability to other microparticle compositions resulting in a microparticle composition with longer shelf life and improved dispersability. The microparticle compositions of the present invention have a transition temperature (Tg) of at least 20° C. above the recommended storage temperature (Tst) for drug delivery.
    Type: Application
    Filed: December 14, 2010
    Publication date: April 7, 2011
    Applicant: NOVARTIS AG
    Inventors: Luis A. Dellamary, Jean Riess, Ernest G. Schutt, Jeffry G. Weers, Thomas E. Tarara
  • Patent number: 7919647
    Abstract: This invention provides a class of androgen receptor targeting agents. The agents define a new subclass of compounds, which are selective androgen receptor modulators (SARM).
    Type: Grant
    Filed: February 16, 2006
    Date of Patent: April 5, 2011
    Assignee: University of Tennessee Research Foundation
    Inventors: James T. Dalton, Duane D. Miller, Yali He, Donghua Yin
  • Publication number: 20110034556
    Abstract: Human skin is treated for cosmetic purposes, in particular for the management of skin irritation and/or inflammation as well as inhibiting ageing effects, which result therefrom by using a topical cream containing at least one transglutaminase inhibitor such as putrescine.
    Type: Application
    Filed: November 27, 2008
    Publication date: February 10, 2011
    Inventor: Kenneth Nicholis Dolynchuk
  • Patent number: 7871602
    Abstract: The use of bis-amines to enhance the antimicrobial activity of pharmaceutical compositions is described. The bis-amines are particularly useful for enhancing the antimicrobial activity of aqueous ophthalmic compositions, such as artificial tears or ocular lubricants, and solutions for disinfecting contact lenses.
    Type: Grant
    Filed: October 3, 2008
    Date of Patent: January 18, 2011
    Assignee: Alcon, Inc.
    Inventors: Nissanke L. Dassanayake, Thomas Christopher Carey, Ronald L. Schlitzer, David L. Meadows
  • Publication number: 20100286270
    Abstract: Germicidal compositions containing one or more N,N-bis(3-aminopropyl) C6-C18 alkyl amines, such as N,N-bis(3-aminopropyl)dodecylamine, and methods of using the compositions for treatment or prevention of infectious hoof diseases are disclosed. The germicidal compositions remain active in the presence of manure, which eliminates the need to pre-clean the hooves before use, and have particular utility for treating or preventing papillomatous digital dermatitis, interdigital phlegmon, interdigital dermatitis, laminitis, white line disease, heel erosion and other hoof diseases.
    Type: Application
    Filed: September 10, 2007
    Publication date: November 11, 2010
    Applicant: DELAVAL HOLDINGS AB
    Inventors: Chris Foret, Alex Skender, Thomas C. Hemling
  • Patent number: 7829543
    Abstract: Disclosed are methods of treating bacterial infections including those caused by multidrug resistant bacteria using polyamine efflux pump inhibiting compounds, including for example N-benzylated polyazaalkanes, N-benzylated polyaminoalkanes, or mixed N-benzylated poly(aza/amino)alkanes, optionally in combination with other drugs such as antibiotics, as well as pharmaceutical compositions thereof.
    Type: Grant
    Filed: January 7, 2004
    Date of Patent: November 9, 2010
    Assignee: Paratek Pharmaceuticals, Inc.
    Inventors: Mark L. Nelson, Michael N. Alekshun
  • Patent number: 7767860
    Abstract: Disclosed herein are substituted amino alcohol anti-mycobacterial agents and/or chelation therapy agents of Formula I, process of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Grant
    Filed: September 3, 2008
    Date of Patent: August 3, 2010
    Assignee: Auspex Pharmaceuticals, Inc
    Inventors: Thomas G. Gant, Sepehr Sarshar
  • Publication number: 20100179368
    Abstract: The present invention relates generally to chemical and biological decontamination solutions and methods of using them. The invention is useful for decontaminating a wide range of compounds and organisms. In particular, the systems, methods, solutions, and formulations of the invention can be used to remove and/or neutralize organophosphates and other toxic chemicals, bacteria, bacterial spores, fungi, molds and viruses.
    Type: Application
    Filed: September 25, 2009
    Publication date: July 15, 2010
    Applicant: Aries Associates, Inc.
    Inventor: Michael J. Conrad
  • Publication number: 20100158818
    Abstract: The present application relates to N-chlorinated cationic compounds of Formula I or a salt thereof, and associated compositions and methods of use as antimicrobial agents.
    Type: Application
    Filed: November 6, 2009
    Publication date: June 24, 2010
    Inventors: Rakesh K. Jain, Eddy Low, Charles Francavilla, Timothy P. Shiau, Satheesh K. Nair
  • Publication number: 20100093868
    Abstract: Disclosed are a water-soluble metal-processing agent and a coolant both of which have excellent microbial deterioration resistance and are less likely to go rotten, a method for preparing the agent or the coolant, and a metal processing method. The water-soluble metal-processing agent or the coolant comprises an N,N,N?,N?-tetraalkyldiamine compound. The metal processing method is characterized by processing a metal of interest by using the water-soluble metal-processing agent or the coolant.
    Type: Application
    Filed: September 21, 2007
    Publication date: April 15, 2010
    Applicant: YUSHIRO CHEMICAL INDUSTRY CO., LTD.
    Inventors: Toru Kadokawa, Akio Saito
  • Publication number: 20090325975
    Abstract: The present invention refers to the use of compounds active on the sigma receptor for the production of a medicament for the treatment of diabetes-associated pain.
    Type: Application
    Filed: July 27, 2006
    Publication date: December 31, 2009
    Inventor: Helmut H Buschmann
  • Publication number: 20090317357
    Abstract: Methods for treating or preventing an autoimmune disease using agents that block the histamine H1 receptor are disclosed. H1 receptor-blocking agents useful in accordance with the methods provided herein include, for example, H1 antihistamines, particularly H1 antihistamines that do not substantially block the serotonin receptor.
    Type: Application
    Filed: February 24, 2004
    Publication date: December 24, 2009
    Inventors: Lawrence Steinman, Rosetta Pedotti
  • Patent number: 7576135
    Abstract: A compound represented by formula (1): Q1-Q2-T0-N(R1)-Q3-N(R2)-T1-Q4??(1) [wherein R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6-membered cyclic hydrocarbon group which may be substituted, or the like; Q2 is a single bond or the like; Q3 represents the following group: (wherein Q5 is an alkylene group having 1 to 8 carbon atoms, or the like); and T0 and T1 are carbonyl groups or the like], a salt thereof, a solvate thereof, or an N-oxide thereof.
    Type: Grant
    Filed: December 25, 2003
    Date of Patent: August 18, 2009
    Assignee: Daiichi Pharmaceutical Co., Ltd.
    Inventors: Toshiharu Ohta, Satoshi Komoriya, Toshiharu Yoshino, Kouichi Uoto, Yumi Nakamoto, Hiroyuki Naito, Akiyoshi Mochizuki, Tsutomu Nagata, Hideyuki Kanno, Noriyasu Haginoya, Kenji Yoshikawa, Masatoshi Nagamochi, Syozo Kobayashi, Makoto Ono
  • Publication number: 20090192173
    Abstract: Methods and compositions for treating disease caused by infectious agents, particularly tuberculosis. In particular, methods and compositions comprising substituted ethylene diamines for the treatment of infectious diseases are provided. In one embodiment, these methods and compositions are used for the treatment of mycobacterial infections, including, but not limited to, tuberculosis. In certain embodiments, the present invention comprises compositions comprising novel substituted ethylene diamine compounds further comprising antitubercular agents such as rifampicin, isoniazid, pyrazinamide and ethambutol.
    Type: Application
    Filed: October 22, 2008
    Publication date: July 30, 2009
    Inventors: Marina Nikolaevna PROTOPOPOVA, Leo Einck, Boris Nikonenko, Ping Chen
  • Patent number: 7445771
    Abstract: The use of bis-amines to enhance the antimicrobial activity of pharmaceutical compositions is described. The bis-amines are particularly useful for enhancing the antimicrobial activity of aqueous ophthalmic compositions, such as artificial tears or ocular lubricants, and solutions for disinfecting contact lenses.
    Type: Grant
    Filed: December 9, 2004
    Date of Patent: November 4, 2008
    Assignee: Alcon, Inc.
    Inventors: Nissanke L. Dassanayake, Thomas Christopher Carey, Ronald L. Schlitzer, David L. Meadows
  • Publication number: 20080234387
    Abstract: The invention relates to novel biocidal active substance mixtures containing o-phenylphenol and amines, methods for the production thereof the use thereof for protecting technical materials and products from being infested and destroyed by microorganisms, and microbicidal agents based on said novel mixtures.
    Type: Application
    Filed: October 6, 2006
    Publication date: September 25, 2008
    Applicant: LANXESS DEUTSCHLAND GMBH
    Inventors: Peter Wachtler, Martin Kugler
  • Publication number: 20080227767
    Abstract: Methods and compositions which are useful in the treatment of amyloidosis. In particular, methods and compositions are provided for inhibiting, preventing and treating amyloid deposition, e.g., in pancreatic islets, wherein the amyloidotic deposits are islet amyloid polypeptide (IAPP)-associated amyloid deposition or deposits. The methods of the invention involve administering to a subject a therapeutic compound which inhibits IAPP-associated amyloid deposits. Accordingly, the compositions and methods of the invention are useful for inhibiting IAPP-associated amyloidosis in disorders in which such amyloid deposition occurs, such as diabetes.
    Type: Application
    Filed: May 22, 2008
    Publication date: September 18, 2008
    Applicant: Neurochem (International) Limited
    Inventors: Walter A. Szarek, Donald F. Weaver, Xianqi Kong, Ajay Gupta, David Migneault
  • Patent number: 7388112
    Abstract: The synthesis and use of a novel class of tumor necrosis factor (TNF?) inhibitors and immunomodulators are provided. Examples are those having the structures: wherein a, b and c are integers from 0 to 12, X equals NH or CHNH2, R1 and R2 each is a hydrogen or a C1 to C20 aliphatic; aliphatic amine; an alicyclic; aromatic; heterocycle; and halogenated forms thereof; and wherein, a, b and c are integers from 0 to 12; R1, R2, R3, and R4 each is a hydrogen or a C1 to C20; aliphatic amine; an alicyclic; aromatic; a heterocycle; and halogenated forms thereof.
    Type: Grant
    Filed: July 1, 2005
    Date of Patent: June 17, 2008
    Assignee: MediQuest Therapeutics, Inc.
    Inventors: Mark R. Burns, Maralee McVean, Kevin Kennedy, Arthur Yeung, Bruce H. Devens
  • Patent number: 7374770
    Abstract: Polyethylene glycol ethers of alkyl alcohols having the general formula CH3(CH2)xCH2(OCH2CH2)nOH wherein x is 8 to 20 (of which ceteareth-20, steareth-20 and steareth-100 are preferred), poloxamer 185, poloxamer 407, N,N-dimethyl dodecylamine N-oxide, and mixtures thereof, are employed to increase follicular delivery and/or follicular residence time of certain water soluble ornithine decarboxylase inhibitors of which 2(difluoromethyl)-2,5-diamino pentanoic acid and its pharmaceutically acceptable salts, hydrates, optical enantiomers and racemic mixture are preferred.
    Type: Grant
    Filed: August 13, 2002
    Date of Patent: May 20, 2008
    Assignee: SkinMedica, Inc.
    Inventors: Joyce T. Chou, Prakash Parab
  • Publication number: 20080114072
    Abstract: N1,N4-bis(buta-1,3-dienyl)butane-1,4-diamine dihydrochloride (also referred to as MDL 72,527 and N,N?-di-2,3-butadienyl-1,4-butanediamine dihydrochloride), or salts or solvates thereof, its use as an antioxidant, its use in preventing and/or treating prostate cancer in male humans, and its use in reducing the concentration of reactive oxygen species in human prostate gland tissue or any other body tissue, and methods of making the compound thereof. Other methods include inhibiting acetyl polyamine oxidase in human prostate tissue or other human body tissue comprising administering a therapeutic amount of N,N?-bis(2,3-butadienyl)-1,4-butanediamine or a salt or solvate thereof to the human, and a method of determining oxidative stress in human prostate tissue or other human or animal body tissue comprising measuring a ratio of oxidized 2?,7?-dichlorodihydrofluorescein diacetate fluorescence:DNA fluorescence and hydroethidine dye fluorescence ex vivo or in vivo.
    Type: Application
    Filed: May 3, 2007
    Publication date: May 15, 2008
    Inventors: Hirak S. Basu, Dawn R. Church, Patrick M. Woster, George Wilding
  • Publication number: 20080027009
    Abstract: A method of protecting skin enzymes from the harmful effects of a cosmetic cleansing preparation which comprises water and one or more anionic surfactants. The method comprises using a cleansing preparation which has a pH value of from 4 to 7 and an SCTE (Stratum Comeum Tryptic Enzyme) value, determined following application of the preparation to human skin and standardized to a value of 100 for tap water, of from 65 to 95. The preparation comprises (i) one or more acyl-/dialkylethylenediamines which reduce the CMC of the one or more anionic surfactants and (ii) a buffer system of citric acid and citrate ions.
    Type: Application
    Filed: March 24, 2005
    Publication date: January 31, 2008
    Applicant: BEIERSDORF AG
    Inventors: Andreas Schepky, Albrecht Doerschner, Ursula Holtzmann, Katrin Counradi, Stephan Ruppert
  • Patent number: 7307071
    Abstract: Materials and methods for treating certain cancers are described, preferably cancers that result from the up-regulation of the RAF-MEK-ERK pathway, and more preferably chronic myelogenous leukemia, and which cancer is preferably resistant to the inhibition of the Bcr-Abl tyrosine kinase, imatinib.
    Type: Grant
    Filed: December 3, 2002
    Date of Patent: December 11, 2007
    Assignee: Onyx Pharmaceuticals, Inc
    Inventors: John F. Lyons, Gideon Bollag
  • Publication number: 20070280890
    Abstract: Disinfectant systems and methods of disinfecting a surface for drying are disclosed. One system comprises a carrier for drying the surface and an anti-microbial component for disinfecting the surface. The ant-microbial component forms a film-free coating containing an organic halogen salt when the carrier evaporates from the surface.
    Type: Application
    Filed: May 30, 2006
    Publication date: December 6, 2007
    Inventor: Joseph Frank Gravlee
  • Patent number: 7276538
    Abstract: The use of the polyamine known as spermidine, i.e., N-(3-aminopropyl) tetraminethylenediamine, as an active principle in the preparation of a composition for pharmaceutical or dietetic use in man for combating hair loss is disclosed.
    Type: Grant
    Filed: January 17, 2003
    Date of Patent: October 2, 2007
    Assignee: Giuliani S.p.A.
    Inventors: Fabio Rinaldi, Elisabetta Sorbellini, Valter Gatti, Danila Ingrid Marchioretto
  • Publication number: 20070203249
    Abstract: This invention relates to a process of treating/affecting cancers that are particularly susceptible to radiation therapy by administering to a host in need of such treatment an amino acid and radiation therapy.
    Type: Application
    Filed: February 14, 2007
    Publication date: August 30, 2007
    Inventor: Leandro Carlos A. Cerchietti
  • Patent number: 7232846
    Abstract: The oral administration to genetically alcoholic rats (from the strain UChB of the University of Chile) of a compound selected from endogenic polyamines (putrescine, spermidine, spermine), 1,3-propanediamine, their pharmaceutically acceptable salts and solvates, and their bioprecursor amides, causes a significant reduction in the alcohol consumption. The activity lasts for some time after the treatment period. Besides, there is a virtually null disulfiram-like adverse effect, what constitutes an advantage over the unpleasant use of some anti-alcoholism agents, such as calcium cyanamide or disulfiram itself. Therefore, the compounds of the invention are useful for the preparation of medicaments for the therapeutic and/or prophylactic treatment of alcoholism in human beings.
    Type: Grant
    Filed: September 19, 2002
    Date of Patent: June 19, 2007
    Assignee: Garbil Pharma Investigacion Chile Ltda.
    Inventors: Norberto Bilbeny Lojo, Hernan Garcia Madrid
  • Patent number: 7202280
    Abstract: Novel methods for treating and preventing acute and/or chronic pancreatitis are described. Additionally, novel methods for inducing liver regeneration are described. The methods may comprise administering to a patient an effective amount of a metabolically stable analogue of spermidine and/or spermine. Preferred compounds for use in the methods may include 1-methylspermidine, 1-methylspermine and 1,12-dimethylspermine.
    Type: Grant
    Filed: December 9, 2003
    Date of Patent: April 10, 2007
    Inventors: Tiina-Liisa Räsänen, Leena Alhonen, Riitta Sinervirta, Tuomo Keinänen, Karl-Heinz Herzig, Alex Radii Khomutov, Jouko Vepsäläinen, Juhani Jänne